Table 2.

Overall survival (OS) and progression-free survival analysis (PFS)

Variables	OS		PFS
	HR (95% CI)	p	HR (95% CI)	p
Age
≤ 66 years	0.8249	0.512	0.7509	0.340
> 66 yearsR	(0.456–1.489)		(0.409–1.376)
Sex
MaleR	1.715	0.060	1.740	0.059
Female	(0.949–3.099)		(0.948–3.193)
ECOG
0R
1	0.790 (0.402–1.556)	0.492	0.6893 (0.348–1.365)	0.288
2–3	0.619 (0.247–1.554)	0.167	0.43 (0.1496–1.236)	0.047
Primary tumor location
HeadR	1.16	0.624	1.295	0.44
Body/tail	(0.596–2.275)		(0.6353–2.640)
Number of metastasis
1	1.19	0.555	1.301	0.383
≥ 2R	(0.652–2.169)		(0.703–2.405)
Metastatic location
HepaticR	2.193	0.029	2.678	0.004
Non-hepatic	(1.163–4.133)		(1.431–5.012)
RAS status in plasma
MUTR	2.605	0.003	2.850	0.0007
WT	(1.425–4.760)		(1.549–5.243)
MAF
> 2.01%R	1.591	0.107	1.813	0.035
< 2.01%	(0.867–2.920)		(0.963–3.409)
CA19-9
> 4515 U/mLR	1.517	0.145	1.554	0.141
< 4515 U/mL	(0.821–2.803)		(0.827–2.920)
cfDNA concentration
> 31.8 ng/mLR	1.858	0.032	1.853	0.034
< 31.8 ng/mL	(0.999–3.451)		(0.973–3.526)
NPTX2 methylation
> 6.06%R	2.190	0.006	1.844	0.032
< 6.06%	(1.186–4.044)		(0.989–3.437)

^RReference category for analysis